AI-generated illustration; not a photograph of the reported event.
- calendar_today November 8, 2026
New Advances from Brigham Young University Researchers
Scientists at Brigham Young University (BYU) have announced the development of a new tool in the fight against cancer. Their innovative immunotechnology, named MOTO-CAR, genetically engineers macrophages—key immune system cells—to target and attack solid tumors. This development has shown significant promise in preclinical studies, paving the way for potential advances in cancer immunotherapy.
MOTO-CAR: Genetically Engineered Macrophages
The MOTO-CAR technology is designed to reprogram macrophages so that they can recognize specific cancer markers. Once modified, these macrophages are capable of entering solid tumors, attacking the cancer cells directly, and activating other immune responses within the body. This approach addresses a longstanding challenge in treating solid tumors, which are often resistant to other types of therapy.
Targeting Difficult-to-Cure Cancers
According to a BYU news release, the MOTO-CAR platform could help treat some of the most challenging cancers, including glioblastoma, triple-negative breast cancer, and pancreatic cancer. These cancers are historically resistant to conventional treatments, making new approaches especially crucial. Lead researcher and BYU professor Kim O’Neill emphasized that the technology could become available within five years if trials and further research continue to prove its effectiveness.
Preclinical Trials Show Encouraging Results
In laboratory studies, the engineered macrophages demonstrated significant efficacy against aggressive cancer cells. In one in vitro experiment, the research team observed a 90% reduction in aggressive lung cancer cells within just 24 hours. Another study in mice showed that a single MOTO-CAR regimen was able to reduce tumor sizes by up to 46%. These preclinical cancer trials highlight the potential of MOTO-CAR as a solid tumor treatment and bolster the case for continued research into this approach.
Potential for Greater Accessibility and Affordability
Beyond effectiveness, one of the key promises of the MOTO-CAR technology is its potential to significantly lower the cost of cancer treatment. Professor Kim O’Neill, who has a personal connection to the cause due to the loss of both parents to cancer, stated that an efficient and more cost-effective therapy could greatly expand patient access to advanced care. O’Neill and his team are committed to moving this research forward, in hopes of reaching patients in need as soon as possible.
Looking Ahead in Immunotherapy Research
BYU’s work with engineered macrophages is the latest sign of growing momentum in immunotherapy research. If successful in further trials, MOTO-CAR may provide an innovative solution for patients facing some of the most difficult cancer diagnoses. The BYU research team continues to focus on demonstrating the effectiveness and safety of this approach, aiming to bring new hope to cancer patients worldwide.
Source: sltrib.com.
